Product
RBMRNA-176
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Phase I/II, Randomized, Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (RBMRNA-176) in Healthy Adults Aged 18 Years and OlderStatus: Completed, Estimated PCD: 2022-09-01